Keymed Biosciences
Keymed Biosciences Inc is a Chinese clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing antibody therapeutics for autoimmune diseases and oncology. The company advances proprietary biologic candidates including stapokibart (CM310), an anti-IL-4Rα monoclonal antibody for atopic dermatitis and asthma, alongside CM313 (anti-CD38) and Claudin18.2 antibody-drug conjugates (ADCs). Principal revenue is driven through commercial sales of approved antibody therapies, strategic licensing upfront fees, and research collaboration milestones with global pharmaceutical partners. Core end markets encompass dermatology practices, allergy clinics, clinical oncology centers, and prescription patients in China and international markets. Keymed Biosciences holds an innovative position in China's biopharmaceutical industry as a specialized developer of novel monoclonal antibody and ADC therapeutics. The company is incorporated in the Cayman Islands, headquartered in Chengdu, China, and listed on the Stock Exchange of Hong Kong.
4 of the funds FundTelligence covers report a position in Keymed Biosciences.
- Legal name
- KEYMED BIOSCIENCES INC
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding Keymed Biosciences
- Nordea Chinese Equity Fund — Nordea Funds · 0.72 % (full portfolio disclosed, September 2026)
- Nordea China — Nordea Funds · 0.71 % (full portfolio disclosed, September 2026)
- ChinaAMC China Opportunities Fund — ChinaAMC · 0.36 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)